Gracias - Shock and Euvolemic Resuscitation
Transcription
Gracias - Shock and Euvolemic Resuscitation
Shock and Euvolemic Resuscitation Vicente H. Gracias MD, FACS, FCCP Associate Professor of Surgery Chief Surgical Critical Care Medical Director Critical Care University of Pennsylvania School of Medicine Hemodynamic Monitoring Multimodality Therapy 1 Agreement of terms Shock • An abnormality of the circulatory system that results in inadequate organ perfusion and tissue oxygenation – International Consensus Conference-Hemodynamic monitoring in shock and implications for management. Intensive Care Medicine (2007) 33:575590 “A momentary pause in the act of death.” -John Collins Warren, 1800s Agreement of Terms Sepsis • Source of infection (positive blood cultures) • Plus two or more (SIRS) – Temperature <36 (0C) or >38 (0C) – Leukocytes <4,000(nL) or > 12,000 or 10% immature cell – Heart rate > 90 beats/minute – Respiratory rate >20 breaths/min or PCO2<32mmHg ACCP/SECM Consensus Conference 1991, published 1992 2 Agreement of Terms Host response Improved specificity for defining SIRS • Sepsis – Clinical syndrome characterized by the presence of both infection and a systemic inflammatory response • Severe sepsis- organ dysfunction, hypoperfusion responsive to volume loading • Septic shock – arterial hypotension, vasopressors • Multiple Organ Dysfunction Syndrome SCCM/ ACCP/ ESICM/ ATS/ SIS Consensus Conference Revised 2001 The Obvious Hemorrhage ↓ Massive transfusion & Shock ↓ Hypothermia Acidosis ∆ Coagulopathy 3 Importance Sepsis incidence • • • • 750,000 new cases/year in US Surviving sepsis campaign- SCCM More than a third trauma related > 50% of surgical patients present with possible infective insult • 20% SIRS/sepsis rate of severely injured patients (ISS >15) • 19%- 43% Mortality Importance Etiology Major Sources • • • • Thoracic/ Pulmonary Intra-abdominal / abscess Extremity wounds/ injured tissue Catheter related complication 4 Importance Abdominal Sepsis • Re-exploration- 3-6% misdiagnosis • CT scan – 10% misdiagnosis • Autopsy results- 3% trauma patients – 1970s to the 2000s 3-5% rate for missed diagnosis of intra-abdominal sepsis among patients who died from MODS CCM 1988, Chest 2001, JACS 2002, SCCM/ESICM Proceedings 2002 Importance ICU Sources- miscellaneous • • • • • • • Wound infection Acalculous cholecystitis Antibiotic-associated colitis Sinusitis and otitis media Meningitis Endocarditis Septic thrombophlebitis 5 Mechanism: Acute phase response One hit Vs Two hit Model One Hit • Single insult initiates SIRS response • Ongoing underresuscitation • • • • • • Two hit Shock- induces PMN priming and activation Blood transfusion Bacterial translocation Second insult Infection- Pneumonia Surgery ACS ACUTE INFLAMMATORY RESPONSE Other: Interferons MIPs Complement CSFs 6 End Results Pulmonary • Blunt Trauma ISS> 15 • Most common organ to fail following severe sepsis • 17% to 40% incidence of pneumonia • H. influenza and Staph. aureus - early • Gram negative – late, VAP Nast-Kolb JOT 2001 7 End results ARDS • • • • • Female sex ISS>20 Multiple Transfusions Pulmonary contusion Multiple fractures (long bones, pelvis) – 25% will develop ARDS End result Intra-abdominal Complications Parameters ATI Crystalloid (L) Fascia closed (%) IAC (n=5) 44.6 +/- 11.7 15.8 +/- 7.4 0/5 (0) No IAC (n=21) 33.1 +/- 11.7 8.2 +/- 6.0 12/16 (75) p value <0.05 <0.05 <0.01 ACS Gracias et.al. 2002 (unpublished ) 8 End result Nutrition & Post-injury Hypercatabolism “Nitrogen death” Muscle Mass Visceral protein Organ Function Immune response “INFECTIONS” Multiple Organ failure Mattox, Moore, Feliciano Fourth edition Multisystem Organ dysfunction • Clinical disorder characterized by the acute but potentially reversible physiologic dysfunction involving at least two organ systems • Infectious Vs inflammatory • Causative – Epi-phenomenon • Changing etiologies – Pulmonary and Abdominal 9 SIRS/Sepsis Multiple Organ Dysfunction Syndrome Number of Organs Mortality (%) 0 1 2 0.8 6.8 26.2 3 48.5 4 5 68.8 83.3 *Adapted from Irwin and Rippe’s Critical Care Medicine 5th Edition, pg 1837 Unfortunately… 10 Shock The Spiral Balanced Physiologic Response Shock • SIRS • CARS- compensatory anti-inflammatory response syndrome • DIC • Apoptosis • MODS/MOF 11 Balanced Resuscitation Shock Imbalance in host immune defense Therapy First Steps • Infection surveillance • Blood cultures/ Physical exam if possible (ileus) • DPL- high negative predictive value • Broad spectrum antibiotics • Mono-therapy as good as classic (Amp/Gent/Flagyl) • Quick D/C if no source identified • Antifungal therapy • Early intervention for non-responders • Within 24-48 hours of suspician • CT scan Vs OR 12 Therapy When to get aggressive? • Aggressive monitoring with early end point resuscitation- ongoing acidosis • Cardiac efficiency • SVO2, Lactate, CVP Oxymetry • Early inotropic support with failed preload • Norepinephrine • Vasopressin • Protective ventilator management • Low tidal volume, best PEEP, low inflation pressures The Problem • Inadequate resuscitation of the patient in shock leads to MODS and/or death • Patients may appear to be adequately resuscitated based on traditional parameters (vital signs, urine output), but have occult hypoperfusion and ongoing tissue acidosis 13 The Problem No agreement • Compensated shock may lead to organ dysfunction and death • What measures can we use to guide our resuscitation? • Do these measures predict survival? • Do these measures improve survival? Hemodynamics Cardiac efficiency • No preload marker is infallible, “ the trend is your friend” • Stoke volume may have better functional correlation with target value 0.75cc to 1cc/kg than CVP or PCWP » Lacking validation • PAC lacks validating outcomes studies. • Some data in severely injured patients 14 Hemodynamics Cardiac efficiency EDEMA ZONE Cardiac Index CVP/Stroke volume/ EDVI PAC Utility • No study has ever proven benefit of PAC on critical care patients • Several studies have pointed toward adverse outcomes • Meta analysis show use of PAC neither increased nor decreased overall mortality or days in hospital nor conferred benefit. 15 16 PAC Utility • Why doesn’t it work? – Data incorrect – Interpretation incorrect – Management schemes incorrect 17 PAC Utility • Why doesn’t it work? – Data incorrect – Interpretation incorrect – Management schemes incorrect 18 PAC Utility • Why doesn’t it work? – Data incorrect – Interpretation incorrect – Management schemes incorrect 19 PAC Utility • Why doesn’t it work? – Data incorrect – Interpretation incorrect – Management schemes incorrect 20 Does RVEDVI indicate preload? • The RVEDVI predicts a CI response to preload better than the PCWP – Diebel 1992, 1994 – Durham 1995 – Chang 1996 21 Hemodynamics in sepsis Determinants of oxygen delivery (DO2) Heart rate Cardiac output DO2 Stroke volume O2 Sat % Oxygen content PaO2 Hct Hemodynamics in sepsis Endpoints of resuscitation C O N S U O M 2 P T I O N Flow Independent Flow Dependent OXYGEN DELIVERY Bishop,Shoemaker :CCM 1993 22 Hemodynamics in sepsis Lactate • Marker of anaerobic metabolism • Classically increased organic acidosis • Metabolized by liver – increased with hepatic dysfunction – Increased with shunting due to sepsis Hemodynamics in sepsis Lactate Weil & Afifi, Circulation 1970. 23 Euvolemic Resuscitation Too MUCH E n d p o i n t Too LITTLE 1/SVO2 Lactate Flow sufficiency Cardiac inefficiency Hemodynamic sufficiency Just RIGHT Flow inefficiency Cardiac efficiency OXYGEN DELIVERY Adapted from: Gracias, McGonigal:SCNA 2000 Sepsis Prophylaxis • Antibiotics- early cessation without source • Enteral nutrition • Sucralfate Vs H2 Blockade • Selective Gut Decontamination • I/S, CPT • Operative Timing 24 Hemodynamics in sepsis Priorities • • • • • Early identification Early initiation of antibiotics Control of septic source Understand hemodynamics Rapid resuscitation and hemodynamic management • Early mechanical ventilation? International Sepsis Forum (ISF) 2001 Rivers NEJM 2001 Discussion 25
Similar documents
Sepsis-Specific Treatment Market Will Expand from 2016 and Reach $354 Million by 2021
Following the first sepsis-specific product launch in 2016, the treatment market will expand at a Compound Annual Growth Rate (CAGR) of 69% to reach $354 million by 2021 across the six major markets (6MM) of the US, UK, France, Germany, Italy and Spain, according to research and consulting.
More information